PL197186A1 - Sposob wytwarzania steroidow - Google Patents
Sposob wytwarzania steroidowInfo
- Publication number
- PL197186A1 PL197186A1 PL19718677A PL19718677A PL197186A1 PL 197186 A1 PL197186 A1 PL 197186A1 PL 19718677 A PL19718677 A PL 19718677A PL 19718677 A PL19718677 A PL 19718677A PL 197186 A1 PL197186 A1 PL 197186A1
- Authority
- PL
- Poland
- Prior art keywords
- steroids
- making
- making steroids
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB13707/76A GB1581234A (en) | 1976-04-05 | 1976-04-05 | 11a - amino - 3a - hydroxysteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL197186A1 true PL197186A1 (pl) | 1979-06-18 |
Family
ID=10027931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19718677A PL197186A1 (pl) | 1976-04-05 | 1977-04-04 | Sposob wytwarzania steroidow |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS52142056A (pl) |
| AU (1) | AU517206B2 (pl) |
| BE (1) | BE853227A (pl) |
| DE (1) | DE2715078A1 (pl) |
| DK (1) | DK148677A (pl) |
| ES (1) | ES457507A1 (pl) |
| FI (1) | FI771046A7 (pl) |
| FR (2) | FR2347382A1 (pl) |
| GB (1) | GB1581234A (pl) |
| IE (1) | IE45276B1 (pl) |
| IL (1) | IL51816A (pl) |
| IT (1) | IT1073232B (pl) |
| LU (1) | LU77064A1 (pl) |
| NL (1) | NL7703667A (pl) |
| NO (1) | NO771197L (pl) |
| NZ (1) | NZ183775A (pl) |
| PL (1) | PL197186A1 (pl) |
| SE (1) | SE7703929L (pl) |
| ZA (1) | ZA772029B (pl) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1173433A (en) * | 1980-07-16 | 1984-08-28 | Gordon H. Phillipps | 11.alpha.-AMINO-ANDROSTANES |
| DE3160797D1 (en) * | 1980-07-16 | 1983-09-29 | Glaxo Group Ltd | 11-alpha-amino androstanes, pharmaceutical compositions containing them and processes for their preparation |
| EP0059637A1 (en) * | 1981-03-02 | 1982-09-08 | Glaxo Group Limited | 11Alpha-amino-3 Beta-hydroxy-androstanes |
| JPS57203100A (en) * | 1981-05-29 | 1982-12-13 | Glaxo Group Ltd | 11 alpha-amino-androstanes |
| DE3260539D1 (en) * | 1981-05-29 | 1984-09-13 | Glaxo Group Ltd | 11-alpha-amino-androstanes |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| CZ300694A3 (en) * | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| FR2910002B1 (fr) * | 2006-12-13 | 2009-01-30 | Sanofi Aventis Sa | Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide |
| JP2010037243A (ja) * | 2008-08-04 | 2010-02-18 | Mitsubishi Rayon Co Ltd | ノルボルネンラクトンモノマーの製造方法 |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CA2918735C (en) * | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) * | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP3728285B1 (en) * | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| BR112021026447A2 (pt) * | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
| CA3143545A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2982775A (en) * | 1957-05-06 | 1961-05-02 | Schering Corp | 11-oximino-, amino- and acylaminosteroids |
-
1976
- 1976-04-05 GB GB13707/76A patent/GB1581234A/en not_active Expired
-
1977
- 1977-04-04 NL NL7703667A patent/NL7703667A/xx not_active Application Discontinuation
- 1977-04-04 FI FI771046A patent/FI771046A7/fi not_active Application Discontinuation
- 1977-04-04 JP JP3768077A patent/JPS52142056A/ja active Pending
- 1977-04-04 DK DK148677A patent/DK148677A/da not_active IP Right Cessation
- 1977-04-04 IT IT48805/77A patent/IT1073232B/it active
- 1977-04-04 ES ES457507A patent/ES457507A1/es not_active Expired
- 1977-04-04 NO NO771197A patent/NO771197L/no unknown
- 1977-04-04 LU LU77064A patent/LU77064A1/xx unknown
- 1977-04-04 NZ NZ183775A patent/NZ183775A/xx unknown
- 1977-04-04 PL PL19718677A patent/PL197186A1/pl unknown
- 1977-04-04 SE SE7703929A patent/SE7703929L/xx unknown
- 1977-04-04 BE BE176410A patent/BE853227A/xx not_active IP Right Cessation
- 1977-04-04 IE IE712/77A patent/IE45276B1/en unknown
- 1977-04-04 IL IL51816A patent/IL51816A/xx unknown
- 1977-04-04 AU AU23942/77A patent/AU517206B2/en not_active Expired
- 1977-04-04 ZA ZA00772029A patent/ZA772029B/xx unknown
- 1977-04-04 DE DE19772715078 patent/DE2715078A1/de not_active Withdrawn
- 1977-04-05 FR FR7710271A patent/FR2347382A1/fr active Granted
-
1981
- 1981-05-25 FR FR8110329A patent/FR2485020A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ZA772029B (en) | 1978-11-29 |
| IE45276B1 (en) | 1982-07-28 |
| FR2485020A1 (fr) | 1981-12-24 |
| GB1581234A (en) | 1980-12-10 |
| NZ183775A (en) | 1979-12-11 |
| NO771197L (no) | 1977-10-06 |
| JPS52142056A (en) | 1977-11-26 |
| NL7703667A (nl) | 1977-10-07 |
| DE2715078A1 (de) | 1977-10-13 |
| BE853227A (fr) | 1977-10-04 |
| AU517206B2 (en) | 1981-07-16 |
| FI771046A7 (pl) | 1977-10-06 |
| IT1073232B (it) | 1985-04-13 |
| AU2394277A (en) | 1978-10-12 |
| FR2347382A1 (fr) | 1977-11-04 |
| IL51816A (en) | 1981-09-13 |
| DK148677A (da) | 1977-10-06 |
| LU77064A1 (pl) | 1979-01-18 |
| ES457507A1 (es) | 1978-03-16 |
| IE45276L (en) | 1977-10-05 |
| FR2347382B1 (pl) | 1982-01-08 |
| IL51816A0 (en) | 1977-06-30 |
| SE7703929L (sv) | 1978-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL201286A1 (pl) | Sposob wytwarzania nowych 1-aryloksy-2-hydroksy-3-alkileno-aminopropanow | |
| PL195088A1 (pl) | Sposob wytwarzania n-fosfonometyloglicyny | |
| PL215007A1 (pl) | Sposob wytwarzania gamma-pironow | |
| PL197372A1 (pl) | Sposob wytwarzania pochodnych kanamycyny | |
| PL198727A1 (pl) | Sposob redukowania sulfotlenkow cefalsporyn | |
| PL199298A1 (pl) | Sposob wytwarzania 2-bromo-6-fluoro-n-2-imidazolidynylideno-benzaminy | |
| PL200534A1 (pl) | Sposob wytwarzania nowych oksadeztiacefalosporyn | |
| PL200583A1 (pl) | Sposob wytwarzania nowych pochodnych benzopiranu | |
| PL199633A1 (pl) | Sposob wytwarzania 5-m-toliloksyuracylu | |
| PL198878A1 (pl) | Sposob wytwarzania pochodnych 2-chlorosulfinyloazetydynonu | |
| PL200605A1 (pl) | Sposob wytwarzania nowych pochodnych metioninoenkefaliny | |
| PL202091A1 (pl) | Sposob wytwarzania gamma-pyronow | |
| PL207237A1 (pl) | Sposob wytwarzania steroidow szeregu pregnanu | |
| PL201133A1 (pl) | Sposob wytwarzania nowych pirydobenzodwuazepinonow | |
| PL202660A1 (pl) | Sposob wytwarzania nowych pochodnych spirooksazolidynodionu | |
| PL195267A1 (pl) | Sposob wytwarzania(2-ketopirolidyno)-alkanokarbonamidow | |
| PL201161A1 (pl) | Sposob wytwarzania nowych pochodnych 9-chloroprednisolonu | |
| PL202697A1 (pl) | Sposob wytwarzania 2-bromo-alfa-ergokryptyny | |
| PL197646A1 (pl) | Sposob wytwarzania pochodnych 1-karbamylouracylu | |
| PL201883A1 (pl) | Sposob wytwarzania nowych pochodnych trans-5a-arylo-dziesieciowodorobenzazepiny | |
| PL190443A1 (pl) | Sposob otrzymywania p-nitrodwufenyloaminy | |
| PL96646B1 (pl) | Sposob wytwarzania alkilo-beta-dl-rybopiranozydow | |
| PL192043A1 (pl) | Sposob wytwarzania polinitrozwiazkow | |
| PL199191A1 (pl) | Sposob wytwarzania nowych glicynoamidow | |
| PL202752A1 (pl) | Sposob wytwarzania nowych pochodnych karbazoilonortropiny |